APA

Marchetti A., Wang L., Magar R., Grossman H. B., Lamm D. L., Schellhammer P. F. & Erwin-Toth P. (20000824). Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. : Clinical therapeutics.

Chicago

Marchetti A, Wang L, Magar R, Grossman H B, Lamm D L, Schellhammer P F and Erwin-Toth P. 20000824. Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. : Clinical therapeutics.

Harvard

Marchetti A., Wang L., Magar R., Grossman H. B., Lamm D. L., Schellhammer P. F. and Erwin-Toth P. (20000824). Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. : Clinical therapeutics.

MLA

Marchetti A, Wang L, Magar R, Grossman H B, Lamm D L, Schellhammer P F and Erwin-Toth P. Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. : Clinical therapeutics. 20000824.